Groombridge, Wu, Baughman & Stone

Firm overview:

Patent litigation firm Groombridge, Wu, Baughman & Stone tries cases in court, in arbitrations and before the International Trade Commission, as well as arguing appeals before the Federal Circuit.

Groombridge Wu has been active before the Patent Trial and Appeal Board (PTAB) since its inception in 2012, filing multiple petitions on its first morning of operation, and has since appeared in dozens of inter partes reviews (IPRs), post-grant reviews, and covered business method reviews on behalf of both petitioners and patent owners.

The team’s PTAB experience includes representing Amgen against biosimilar applicants in defending against multiple IPRs, Twitter (now X) against Blackberry in IPR proceedings, and Genentech in multiple IPR matters.

In the district courts, Groombridge Wu has been involved in notable cases representing clients including Amgen, Edwards Lifesciences, Garmin, Google, and Biogen.

Team overview:

Over 35 years, Nicholas Groombridge has been lead counsel in over 150 patent cases in federal district courts, tried dozens of bench and jury trials, and successfully argued more than 30 cases in the Court of Appeals for the Federal Circuit.

Groombridge has litigated patents across technical areas including software, semiconductors, pharmaceuticals, biotechnology and medical devices.

Key matters:

• Novo Nordisk v Mylan Pharmaceuticals

Along with counsel from Morris Nichols, Groombridge Wu represents Novo Nordisk in a suit against Mylan Pharmaceuticals over a patent for Wegovy.

In a complaint filed in March 2025, Novo Nordisk claimed that Mylan’s generic version of its blockbuster weight loss drug infringes a patent issued the month before.

That patent—US patent number 12,214,017—is one of several asserted against Mylan/Viatris.

Clients:

Novo Nordisk